Core Viewpoint - Manulife Financial Corporation (00945) plans to initiate a "normal course issuer bid" subject to approval from the Toronto Stock Exchange, allowing the company to repurchase and cancel up to 42 million common shares, representing approximately 2.5% of its issued and outstanding common shares [1] Group 1 - The "normal course issuer bid" has been approved by the Office of the Superintendent of Financial Institutions Canada [1] - As of January 31, 2026, Manulife has a total of 1.6767 billion issued and outstanding common shares [1] - The repurchase plan is part of Manulife's capital management strategy aimed at maintaining a robust regulatory capital ratio while also creating value for shareholders [1]

Core Viewpoint - Manulife Financial Corporation (00945) plans to initiate a "normal course issuer bid" subject to approval from the Toronto Stock Exchange, allowing the company to repurchase and cancel up to 42 million common shares, representing approximately 2.5% of its issued and outstanding common shares [1] Group 1 - The "normal course issuer bid" plan has been approved by the Office of the Superintendent of Financial Institutions Canada [1] - As of January 31, 2026, Manulife has a total of 1.6767 billion issued and outstanding common shares [1] - The plan is part of Manulife's capital management strategy aimed at maintaining a robust regulatory capital ratio while also creating value for shareholders [1]

Group 1 - The company Manulife Financial-S (00945) announced a dividend distribution of CAD 0.485 per common share for the fourth quarter, scheduled for March 19, 2026 [1]

Group 1 - The company Manulife Financial Corporation (00945) announced a dividend distribution of CAD 0.485 per common share for the fourth quarter, scheduled for March 19, 2026 [1]

Core Insights - The company reported a record core profit of CAD 7.5 billion for the year 2025, representing a 3% increase compared to 2024 on a constant currency basis [1] - The fourth quarter core profit reached CAD 2 billion, up 5% from the same quarter in 2024 [1] - The net income attributable to shareholders for 2025 was CAD 5.6 billion, an increase of CAD 200 million from 2024, while the fourth quarter net income was CAD 1.5 billion, down CAD 100 million from the fourth quarter of 2024 [1] Financial Performance - The core EPS for 2025 was CAD 4.21, an 8% increase from 2024, with the fourth quarter core EPS at CAD 1.12, up 9% year-over-year [1] - The core ROE for the full year and fourth quarter were 16.5% and 17.1%, respectively [1] - APE sales increased by 14% for 2025 compared to 2024, while new business CSM rose by 28% and new business value increased by 18% [1] - In the fourth quarter of 2025, APE sales decreased by 1% compared to the same quarter in 2024, while new business CSM grew by 21% and new business value increased by 8% [1] Strategic Initiatives - The CEO highlighted 2025 as a significant year for the company, achieving record core profits and executing targeted strategic investments [2] - The company recorded over 20% growth in new business CSM across all insurance segments, establishing a solid foundation for future profitability [2] - Strategic moves included the acquisition of Comvest Credit Partners, a joint venture with Mahindra to enter the Indian life insurance market, and the establishment of a high-net-worth client office in Dubai [2] - The company was recognized as the top life insurer in AI maturity and responsible innovation, reflecting its commitment to becoming an AI-driven enterprise [2]

Core Insights - The company reported a record core profit of CAD 7.5 billion for the year 2025, representing a 3% increase compared to 2024 on a constant currency basis [1] - The fourth quarter core profit reached CAD 2 billion, up 5% from the fourth quarter of 2024 [1] Financial Performance - Net income attributable to shareholders for 2025 was CAD 5.6 billion, an increase of CAD 200 million from 2024 [1] - The fourth quarter net income attributable to shareholders was CAD 1.5 billion, a decrease of CAD 100 million compared to the fourth quarter of 2024 [1] - Core EPS for 2025 was CAD 4.21, an 8% increase from 2024 [1] - The fourth quarter core EPS was CAD 1.12, a 9% increase from the fourth quarter of 2024 [1] Key Metrics - The core ROE for 2025 was 16.5%, while the fourth quarter ROE was 17.1% [1] - APE sales increased by 14% for the year 2025 compared to 2024 [1] - New business CSM rose by 28% and new business value increased by 18% for the year 2025 compared to 2024 [1] - For the fourth quarter of 2025, APE sales decreased by 1% compared to the fourth quarter of 2024, while new business CSM increased by 21% and new business value rose by 8% [1] Strategic Initiatives - The CEO highlighted 2025 as a significant year for the company, with targeted strategic investments and optimized corporate strategies [2] - The company achieved over 20% growth in new business CSM across all insurance segments, establishing a solid foundation for future profitability [2] - Strategic acquisitions and partnerships, including the acquisition of Comvest Credit Partners and a joint venture in the Indian life insurance market, were emphasized as part of the diversified business strategy [2] - The company was recognized as the top life insurance company in AI maturity and responsible innovation, reflecting its commitment to becoming an AI-driven enterprise [2]

宏利金融有限公司 大會及記錄日期通告 副總法律顧問（公司治理、投資及交易）兼公司秘書 二零二六年二月十一日 200 Bloor Street East, Toronto, Ontario, Canada M4W 1E5 Tel: 416-926-3000 www.manulife.com 兹根據 《National Instrument 第 54-101 條「與申報發行人證券的實益擁有人之通訊」》的規定， 特此通知如下： | 申報發行人名稱 | 宏利金融有限公司 | | --- | --- | | 大會舉行日期 | 二零二六年五月十四日 | | 通告記錄日期 | 二零二六年三月十六日 | | 投票記錄日期 | 二零二六年三月十六日 | | 實益股權確定日期 | 二零二六年三月十六日 | | 有權收取通告之證券 | 普通股 | | 有權投票之證券 | 普通股 | | ISIN/CUSIP 號碼 | CA56501R1064 / 56501R106 | | 大會類別 | 周年大會 | | 為登記擁有人採用「Notice-and-Access」系統 | 是 | | 為實益擁有人採用「Notice-and-Acces ...

Core Viewpoint - Manulife Financial reported record core earnings and insurance new business performance for the year ending December 31, 2025, with a 10.2% increase in common stock dividends [1] Financial Performance - For 2025, core earnings reached CAD 7.5 billion, a 3% increase from 2024 on a constant currency basis [1] - Q4 2025 core earnings were CAD 2 billion, up 5% compared to Q4 2024 [1] - Net income attributable to shareholders for 2025 was CAD 5.6 billion, an increase of CAD 200 million from 2024 [1] - Q4 2025 net income attributable to shareholders was CAD 1.5 billion, down CAD 100 million from Q4 2024 [1] - Core EPS for 2025 was CAD 4.21, an 8% increase from 2024 [1] - Q4 2025 core EPS was CAD 1.12, a 9% increase from Q4 2024 [1] Return on Equity (ROE) and Sales Performance - The core ROE for 2025 was 16.5%, while the ROE for the same year was 12.0% [2] - Q4 2025 core ROE was 17.1%, and the ROE was 12.7% [2] - APE sales for 2025 increased by 14% compared to 2024, while new business CSM rose by 28% and new business value increased by 18% [2] - APE sales for Q4 2025 decreased by 1% compared to Q4 2024, with new business CSM up by 21% and new business value up by 8% [2] Strategic Initiatives - The CEO highlighted 2025 as a significant year for the company, achieving record core earnings and executing targeted strategic investments [3] - The company recorded over 20% growth in new business CSM across all insurance segments, establishing a solid foundation for future profitability [3] - Strategic actions included acquiring Comvest Credit Partners, forming a joint venture with Mahindra for the Indian life insurance market, and establishing a high-net-worth client office in Dubai [3] - The company was recognized as the leading life insurer in AI maturity and responsible innovation, reflecting its commitment to becoming an AI-driven enterprise [3] - Looking ahead to 2026, the company aims to leverage its diverse business portfolio and strong execution capabilities to achieve sustainable long-term growth despite macroeconomic uncertainties [3]

Core Viewpoint - Manulife Financial Corporation (00945.HK) plans to initiate a "normal course issuer bid" subject to approval from the Toronto Stock Exchange, allowing the company to repurchase and cancel up to 42 million common shares, representing approximately 2.5% of its issued and outstanding common shares [1] Group 1 - The "normal course issuer bid" plan has been approved by the Office of the Superintendent of Financial Institutions Canada [1] - As of January 31, 2026, Manulife has approximately 1.6767 billion issued and outstanding common shares [1] - The repurchase of common shares is part of Manulife's capital management strategy aimed at maintaining a robust regulatory capital ratio while also creating value for shareholders [1]

新聞稿 除非另有註明，所有金額均按加元呈列 TSX/NYSE/PSE: MFC SEHK: 945 此外，宏利可根據適用法律，在加拿大及美國以外地區回購其普通股。在獲得監管機構批准的 前提下，宏利亦可根據適用的證券監管機構頒佈的發行人要約豁免令，以私人協議方式直接向 其他持有人購入普通股。根據證券監管機構頒佈的豁免令進行的任何私人購股交易，一般會以 較當時市價有折讓的價格進行。宏利亦可採用衍生工具相關安排支援其回購活動，包括沽售認 沽期權、訂立遠期購股協議、加速股份回購交易、其他股權合約，或以其他方式購入股份。上 述任何安排均須獲得監管機構批准，並按適用證券法在獲許可的條款及時間内進行。通過「常 規發行人要約」及所有其他可能安排回購的普通股總數，將不會超過4,200萬股。 在獲得監管機構批准的前提下，宏利有意不時與註冊投資經紀商訂立既定計劃，以便在宏利因 內部交易禁售期、內幕交易規則或其他因素而通常無法在市場上進行回購時，仍可購入其普通 股。任何此等計劃均須按照適用的加拿大證券法例及美國聯邦證券法例制定。 即時發佈 2026年2月11日 宏利宣佈計劃啓動「常規發行人要約」計劃 加拿大多倫多 – 宏利金融有限公 ...